Clinical implications of aspirin resistance

References

• Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet367, 606–617 (2006).
   PubMed Web of Science ®Google Scholar
• Pamukcu B. A review of aspirin resistance; definition, possible mechanisms, detection with platelet function tests, and its clinical outcomes. J. Thromb. Thrombolysis23, 213–222 (2006).
   PubMed Web of Science ®Google Scholar
• Anti-thrombotic Trialists Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. Br. Med. J.324, 71–86 (2002).
   PubMed Web of Science ®Google Scholar
• van Gijn J. Aspirin: dose and indications in modern stroke prevention. Neurol. Clin.10(1), 193–207 (1992).
   PubMed Web of Science ®Google Scholar
• Tran HA, Anand SS, Hankey GJ, Eikelboom JW. Aspirin resistance. Thromb. Res.120(3), 337–346 (2007).
   PubMed Web of Science ®Google Scholar
• Dalen JE. Aspirin resistance: is it real? Is it clinically significant? Am. J. Med.120, 1–4 (2007).
   PubMed Web of Science ®Google Scholar
• Faraday N, Becker DM, Yanek LR et al. Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. Am. J. Cardiol.98(6), 774–779 (2006).
   PubMed Web of Science ®Google Scholar
• Harrison P, Frelinger AL 3rd, Furman MI, Michelson AD. Measuring antiplatelet drug effects in the laboratory. Thromb. Res.120, 323–336 (2007).
   PubMed Web of Science ®Google Scholar
• Michelson AD. Platelet function testing in cardiovascular diseases. Circulation110, 489–493 (2004).
   PubMedGoogle Scholar
• Patrono C. Aspirin resistance: definition, mechanisms, and clinical read-outs. J. Thromb. Haemost.1, 1710–1713 (2003).
   PubMed Web of Science ®Google Scholar
• Roth GJ, Calverley DC. Aspirin, platelets and thrombosis: theory and practice. Blood83, 885–898 (1994).
   PubMed Web of Science ®Google Scholar
• Karim S, Habib A, Levy-Toledano S, Maclouf J. Cyclooxygenase-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J. Biol. Chem.271, 12042–12048 (1996).
   PubMed Web of Science ®Google Scholar
• Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schrör K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet353, 900 (1999).
   PubMed Web of Science ®Google Scholar
• Patrignani P, Sciulli MG, Manarini S, Santini G, Cerletti C, Evangelista. V. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J. Physiol. Pharmacol.50, 661–667 (1999).
   PubMed Web of Science ®Google Scholar
• Fitzgerald GA, Oates JA, Hawiger J et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J. Clin. Invest.71, 676–688 (1983).
   PubMed Web of Science ®Google Scholar
• Feuring M, Schultz A, Losel R, Wehling M. Monitoring acetylsalicylic acid effects with the platelet function analyzer PFA-100. Semin. Thromb. Hemost.31(4), 411–415 (2005).
   PubMed Web of Science ®Google Scholar
• Malinin A, Spergling M, Muhlestein B, Steinhubl S, Serebruany V. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul. Fibrinolysis15, 295–301 (2004).
   PubMed Web of Science ®Google Scholar
• Malinin AI, Atar D, Callahan KP, McKenzie ME, Serebruany VL. Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease. Eur. J. Pharmacol.462, 139–143 (2003).
   PubMed Web of Science ®Google Scholar
• Grotemeyer KH, Scharafinski HW, Husstedt IW. Two year follow-up of aspirin responders and aspirin non-responders. A pilot study including 180 post-stroke patients. Thromb. Res.71, 397–403 (1993).
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation105, 1650–1655 (2002).
   Google Scholar
• Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J. Am. Coll. Cardiol.41, 961–965 (2003).
   PubMed Web of Science ®Google Scholar
• Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J. Neurol.250, 63–66 (2003).
   PubMed Web of Science ®Google Scholar
• Buchanan MR, Schwartz L, Bourassa M, Brister SJ, Penistan CM. BRAT Investigators. Results of the BRAT study - a pilot study investigating the possible significance of aspirin non-responsiveness on the benefits and risks of aspirin on thrombosis in patients undergoing CABG. Can. J. Cardiol.16, 1385-1390 (2000).
   PubMed Web of Science ®Google Scholar
• Carney RM, Freedland KE, Eisen SA, Rich MW, Skala JA, Jaffe AS. Adherence to a prophylactic medication regimen in patients with symptomatic versus asymptomatic ischemic heart disease. Behav. Med.24, 35–39 (1998).
   PubMed Web of Science ®Google Scholar
• Tarjan J, Salamon A, Jáger R et al. The rate of acetylsalicylic acid non-respondents among patients hospitalized for acute coronary disease, previously undergoing secondary salicylic acid prophylaxis. Orv. Hetil.140, 2339–2343 (1999).
   PubMedGoogle Scholar
• Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am. J. Cardiol.95, 973–975 (2005).
   PubMed Web of Science ®Google Scholar
• Roller RE, Dorr A, Ulrich S, Pilger E. Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer PFA-100. Blood Coagul. Fibrinolysis13, 277–281 (2002).
   PubMed Web of Science ®Google Scholar
• Kannan S. Pathophysiological impact of transcellular metabolism for the induction of clinical aspirin resistance. Med. Hypotheses66(6), 1252–1253 (2006).
   PubMed Web of Science ®Google Scholar
• Smith CJ, Steichen TJ, Fischer TH. Platelet aggregation in cigarette smokers: a meta-analysis. Inhal. Toxicol.10, 765–793 (1998).
   Web of Science ®Google Scholar
• Eikelboom JW, Hankey GJ, Thom J et al. Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. J. Thromb. Haemost.3, 2649–2655 (2005).
   PubMed Web of Science ®Google Scholar
• O’Donnell CJ, Larson MG, Feng D et al. Genetic and environmental contributions to platelet aggregation: The Framingham Heart Study. Circulation103, 3051–3056 (2001).
   PubMed Web of Science ®Google Scholar
• Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N. Engl. J. Med.348, 538–549 (2003).
   PubMed Web of Science ®Google Scholar
• Fujiwara T, Ikeda M, Esumi K et al. Exploratory aspirin resistance trial in healthy Japanese volunteers (J-ART) using platelet aggregation as a measure of thrombogenicity. Pharmacogenomics J. (2007) [Epub ahead of print].
   PubMedGoogle Scholar